SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2138091

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2138091

Biological Safety Cabinet Market by Type (Class I, Class II [Type A, Type B, Type C1], Class III), End User (Pharma & Biopharma Organization, Clinical Laboratories, Academic & Biomedical Research Institutes, Others), and Region - Global Forecast to 2031

PUBLISHED:
PAGES: 219 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

List of Tables

The global biological safety cabinet market is anticipated to grow from USD 0.26 billion in 2026 to USD 0.36 billion by 2031, reflecting a CAGR of 6.6%. The global biological safety cabinet market is anticipated to grow steadily, supported by increasing investments in pharmaceutical and biopharmaceutical research, expansion of clinical and academic laboratories, and growing requirements for safe handling of infectious and hazardous biological materials.

Scope of the Report
Years Considered for the Study2026-2031
Base Year2025
Forecast Period2026-2031
Units ConsideredValue (USD billion)
SegmentsBy Product, Type, End User
Regions coveredNorth America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa

Demand is further supported by the development of vaccines, biologics, cell and gene therapies, and microbiology applications that require controlled containment environments. Class II cabinets remain the primary product category because they provide personnel, product, and environmental protection and are widely used across research, pharmaceutical, and clinical laboratory settings.

Biological Safety Cabinet Market - IMG1

"Class II to register the highest CAGR in the biological safety cabinet market from 2026 to 2031"

Based on type, the Class II segment is likely to register the highest CAGR during the forecast period. The segment is primarily driven by its ability to provide personnel, product, and environmental protection, making Class II cabinets widely applicable across pharmaceutical, biopharmaceutical, clinical, academic, and microbiology laboratories. Class II BSCs are designed for work involving Biosafety Levels 1, 2, and 3 and support applications such as cell culture and microbiological research. The expansion of pharmaceutical and biopharmaceutical research, clinical diagnostics, infectious disease studies, and academic laboratory infrastructure, coupled with replacement of aging equipment and increasing emphasis on certified containment systems, is expected to sustain demand for Class II biological safety cabinets. NSF/ANSI 49 specifically establishes design, performance, and certification requirements for Class II biosafety cabinetry.

"Pharma & biopharma organizations captured the largest share of the biological safety cabinet market in 2025"

Based on end user, pharma & biopharma organizations accounted for the largest market share in 2025, supported by extensive use of biological safety cabinets in drug discovery, biologics development, vaccine research, cell and gene therapy, quality control, and sterile drug preparation. These organizations require controlled containment for handling microorganisms, biological samples, and potentially hazardous materials, creating sustained demand for Class II biological safety cabinets. The expansion of biopharmaceutical research and manufacturing facilities, along with increasing investments in laboratory infrastructure, is further supporting cabinet installations. Thermo Fisher Scientific identifies pharmaceutical, biotechnology, and clinical facilities among key application settings for its Class II biological safety cabinets.

"Asia Pacific to register the fastest growth rate in the biological safety cabinet market between 2026 and 2031"

Based on region, Asia Pacific is expected to register the fastest growth during the forecast period. Regional expansion is supported by increasing investments in pharmaceutical and biopharmaceutical manufacturing, expansion of clinical and diagnostic laboratories, and growing research activities across China, India, Japan, South Korea, and other emerging economies. The region's expanding biotechnology sector, increasing vaccine and biologics development, and development of new research and healthcare facilities are generating demand for biological safety cabinets. China and India are particularly important growth markets, supported by expanding pharmaceutical and biotechnology industries and investments in laboratory infrastructure. The market presents significant growth opportunities through the modernization of laboratory infrastructure, increasing adoption of certified containment equipment, and expansion of biopharmaceutical and clinical research capabilities. Growing emphasis on laboratory biosafety and contamination control is encouraging laboratories to replace conventional or aging equipment with advanced Class II cabinets offering improved airflow control, energy efficiency, and monitoring capabilities.

Breakdown of primary participants in the biological safety cabinet market is as follows:

  • By Company Type: Tier 1 (32%), Tier 2 (41%), and Tier 3 (27%)
  • By Designation: C-level Executives (30%), Directors (26%), and Others (44%)
  • By Region: North America (53%), Europe (21%), Asia Pacific (17%), Latin America (6%), and the Middle East & Africa (4%)

Key players in the biological safety cabinet market are Thermo Fisher Scientific Inc. (US), Kewaunee Scientific Corporation (US), Labconco Corporation (US), The Baker Company, Inc. (US), Esco Lifesciences (Singapore), Air Science (US), Cruma, S.A. (Spain), Berner International GmbH (USA), LaboGene ApS (Denmark), Biolab Scientific Ltd. (Canada), LAMSYSTEMS GmbH (Germany), and FASTER S.r.l. (Italy).

Research Coverage:

This research report categorizes the biological safety cabinet market by type (Class I, Class II, Class III), end user (Pharma & Biopharma Organizations, Clinical Laboratories, Academic & Biomedical Research Institutes, Other End Users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the biological safety cabinet market. A detailed analysis of key industry players has been conducted to provide insights into their business overview, solutions, and key strategies, such as partnerships, collaborations, expansions, agreements, product launches, and recent developments in the market. This report covers the competitive analysis of upcoming startups in the biological safety cabinet ecosystem.

Reasons to Buy This Report:

The report will help leaders/new entrants in this market by providing information on the closest approximations of revenue for the overall biological safety cabinet market and its subsegments. This report will help stakeholders understand the competitive landscape and gain deeper insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

  • Analysis of key drivers (Rising pharmaceutical and biopharmaceutical R&D activities, Rapid growth in biologics, cell and gene therapies, increasing risk of pandemics and communicable diseases, Growing concerns over cell culture contamination, Expansion of clinical diagnostics and microbiology laboratories), restraints (Availability of alternative containment cabinets, High acquisition and installation costs) opportunities (Growth opportunities in emerging economies, Development of smart and connected biological safety cabinets) and Challenges (Stringent and evolving regulatory requirements across regions, Shortage of qualified service and maintenance personnel) influencing the biological safety cabinet market growth
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the biological safety cabinet market
  • Market Development: Comprehensive information about lucrative markets; the report analyzes the biological safety cabinet market across varied regions
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the biological safety cabinet market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Thermo Fisher Scientific Inc. (US), Kewaunee Scientific Corporation (US), Labconco Corporation (US), and The Baker Company, Inc. (US).
Show more
Product Code: MD 6299

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
    • 1.3.2 INCLUSIONS AND EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

  • 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS SHAPING MARKET
  • 2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS
  • 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 BIOLOGICAL SAFETY CABINET MARKET OVERVIEW
  • 3.2 BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2026 VS. 2031
  • 3.3 BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2026 VS. 2031
  • 3.4 BIOLOGICAL SAFETY CABINET MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Growing biological development and biopharmaceutical activity
      • 4.2.1.2 Increasing investments in laboratory infrastructure
      • 4.2.1.3 Rising emphasis on laboratory biosafety and contamination control
      • 4.2.1.4 Persistent burden of infectious diseases and pathogenic agents
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 High installation, certification, and maintenance requirements
      • 4.2.2.2 High cost of biological safety cabinets
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Growth opportunities in emerging markets
      • 4.2.3.2 Technological advancements in biological safety cabinets
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Shortage of skilled personnel for BSC certification and maintenance
  • 4.3 UNMET NEEDS AND WHITE SPACES
    • 4.3.1 UNMET NEEDS IN BIOLOGICAL SAFETY CABINET MARKET
    • 4.3.2 WHITE SPACE OPPORTUNITIES
  • 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
    • 4.4.1 INTERCONNECTED MARKETS
    • 4.4.2 CROSS-SECTOR OPPORTUNITIES
  • 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
    • 4.5.1 KEY MOVES AND STRATEGIC FOCUS

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 THREAT OF NEW ENTRANTS
    • 5.1.2 THREAT OF SUBSTITUTES
    • 5.1.3 BARGAINING POWER OF BUYERS
    • 5.1.4 BARGAINING POWER OF SUPPLIERS
    • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.2 MACROECONOMIC INDICATORS
    • 5.2.1 INTRODUCTION
    • 5.2.2 GDP TRENDS AND FORECAST
  • 5.3 SUPPLY CHAIN ANALYSIS
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 ECOSYSTEM ANALYSIS
    • 5.5.1 BIOLOGICAL SAFETY CABINET MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • 5.6 PRICING ANALYSIS
    • 5.6.1 AVERAGE SELLING PRICE, BY KEY PLAYER, 2024-2026
    • 5.6.2 AVERAGE SELLING PRICE, BY REGION, 2024-2026
  • 5.7 TRADE ANALYSIS
    • 5.7.1 IMPORT SCENARIO (HS CODE 8414.70)
    • 5.7.2 EXPORT SCENARIO (HS CODE 8414.70)
  • 5.8 KEY CONFERENCES & EVENTS, 2026-2027
  • 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.10 INVESTMENT & FUNDING SCENARIO
  • 5.11 IMPACT OF 2025 US TARIFFS-BIOLOGICAL SAFETY CABINET MARKET
    • 5.11.1 INTRODUCTION
    • 5.11.2 KEY TARIFF RATES
    • 5.11.3 PRICE IMPACT ANALYSIS
    • 5.11.4 IMPACT ON REGIONS
      • 5.11.4.1 North America
      • 5.11.4.2 Europe
      • 5.11.4.3 Asia Pacific
    • 5.11.5 IMPACT ON END-USE INDUSTRIES
      • 5.11.5.1 Pharmaceutical & biopharmaceutical companies
      • 5.11.5.2 Clinical laboratories

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

  • 6.1 KEY EMERGING TECHNOLOGIES
    • 6.1.1 HEPA FILTRATION
    • 6.1.2 AIRFLOW & CONTAINMENT CONTROL
  • 6.2 COMPLEMENTARY TECHNOLOGIES
    • 6.2.1 DECONTAMINATION TECHNOLOGY
  • 6.3 ADJACENT TECHNOLOGIES
    • 6.3.1 LABORATORY ENVIRONMENTAL MONITORING SYSTEMS
  • 6.4 TECHNOLOGY/PRODUCT ROADMAP
  • 6.5 PATENT ANALYSIS
    • 6.5.1 LIST OF MAJOR PATENTS
  • 6.6 FUTURE APPLICATIONS
  • 6.7 IMPACT OF AI/GENERATIVE AI ON BIOLOGICAL SAFETY CABINET MARKET
    • 6.7.1 INTRODUCTION
    • 6.7.2 TOP USE CASES AND MARKET POTENTIAL
    • 6.7.3 KEY COMPANIES IMPLEMENTING AI
    • 6.7.4 FUTURE OF AI/GEN AI

7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES

  • 7.1 REGIONAL REGULATIONS AND COMPLIANCE
    • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.2 SUSTAINABILITY INITIATIVES
    • 7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN BIOLOGICAL SAFETY CABINET
      • 7.2.1.1 Eco-friendly Initiatives
  • 7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

  • 8.1 DECISION-MAKING PROCESS
  • 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
    • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 8.2.2 BUYING CRITERIA
  • 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • 8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
  • 8.5 MARKET PROFITABILITY
    • 8.5.1 REVENUE POTENTIAL
    • 8.5.2 COST DYNAMICS
    • 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS

9 BIOLOGICAL SAFETY CABINET MARKET, BY TYPE

  • 9.1 INTRODUCTION
  • 9.2 CLASS I
    • 9.2.1 BASIC CONTAINMENT REQUIREMENTS SUSTAIN CLASS I CABINET DEMAND
  • 9.3 CLASS II
    • 9.3.1 CLASS II TYPE A
      • 9.3.1.1 Class II Type A1
        • 9.3.1.1.1 Established laboratory installations maintain Type A1 demand
      • 9.3.1.2 Class II Type A2
        • 9.3.1.2.1 Broad biological workflows drive Type A2 demand
    • 9.3.2 CLASS II TYPE B
      • 9.3.2.1 Class II Type B1
        • 9.3.2.1.1 Specialized chemical-biological applications support Type B1 demand
      • 9.3.2.2 Class II Type B2
        • 9.3.2.2.1 Total-exhaust requirements support specialized Type B2 demand
    • 9.3.3 CLASS II TYPE C1
      • 9.3.3.1 Flexible exhaust configurations create a differentiated Type C1 niche
  • 9.4 CLASS III
    • 9.4.1 MAXIMUM-CONTAINMENT REQUIREMENTS SUPPORT CLASS III CABINET DEMAND

10 BIOLOGICAL SAFETY CABINET MARKET, BY END USER

  • 10.1 INTRODUCTION
  • 10.2 PHARMA & BIOPHARMA ORGANIZATIONS
    • 10.2.1 RISING BIOLOGICS DEVELOPMENT AND R&D INVESTMENT TO DRIVE HIGH-END BSC ADOPTION
  • 10.3 CLINICAL LABORATORIES
    • 10.3.1 RISING DISEASE BURDEN AND DIAGNOSTIC TESTING VOLUMES TO SUPPORT MARKET GROWTH
  • 10.4 ACADEMIC & BIOMEDICAL RESEARCH INSTITUTES
    • 10.4.1 SUSTAINED RESEARCH FUNDING TO SHAPE MARKET GROWTH
  • 10.5 OTHER END USERS

11 BIOLOGICAL SAFETY CABINET MARKET, BY REGION

  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    • 11.2.1 US
      • 11.2.1.1 Growth in biosimilars market to boost preclinical research
    • 11.2.2 CANADA
      • 11.2.2.1 Government support for R&D to support market growth
  • 11.3 EUROPE
    • 11.3.1 GERMANY
      • 11.3.1.1 Increased pharmaceutical R&D and biomanufacturing investments to drive market growth
    • 11.3.2 UK
      • 11.3.2.1 Expanding biopharmaceutical R&D to support market growth
    • 11.3.3 FRANCE
      • 11.3.3.1 Expansion of biopharmaceutical manufacturing to support market growth
    • 11.3.4 ITALY
      • 11.3.4.1 Expansion of biomedical research to support market growth
    • 11.3.5 SPAIN
      • 11.3.5.1 Expansion of biomedical research to support market growth
    • 11.3.6 REST OF EUROPE
  • 11.4 ASIA PACIFIC
    • 11.4.1 CHINA
      • 11.4.1.1 Government support for innovative drug development to support market growth
    • 11.4.2 JAPAN
      • 11.4.2.1 Strong academic-industry collaboration to support market growth
    • 11.4.3 INDIA
      • 11.4.3.1 Expansion of biotechnology research and biomanufacturing to support market growth
    • 11.4.4 REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    • 11.5.1 EXPANSION OF PHARMACEUTICAL R&D AND CLINICAL RESEARCH TO SUPPORT MARKET GROWTH
  • 11.6 MIDDLE EAST & AFRICA
    • 11.6.1 INCREASING CLINICAL RESEARCH AND BIOTECHNOLOGY ACTIVITIES TO DRIVE MARKET GROWTH

12 COMPETITIVE LANDSCAPE

  • 12.1 INTRODUCTION
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 12.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN BIOLOGICAL SAFETY CABINET MARKET
  • 12.3 REVENUE ANALYSIS, 2023-2025
  • 12.4 MARKET SHARE ANALYSIS, 2025
    • 12.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
      • 12.5.5.1 Company footprint
      • 12.5.5.2 Region footprint
      • 12.5.5.3 Type footprint
      • 12.5.5.4 End-user footprint
  • 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 RESPONSIVE COMPANIES
    • 12.6.3 DYNAMIC COMPANIES
    • 12.6.4 STARTING BLOCKS
    • 12.6.5 COMPANY FOOTPRINT: STARTUPS/SMES, 2025
      • 12.6.5.1 Detailed list of key startups/SMEs
  • 12.7 COMPANY VALUATION & FINANCIAL METRICS
    • 12.7.1 FINANCIAL METRICS
    • 12.7.2 COMPANY VALUATION
  • 12.8 BRAND/PRODUCT COMPARISON
  • 12.9 COMPETITIVE SCENARIO
    • 12.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
    • 12.9.2 DEALS
    • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

  • 13.1 KEY PLAYERS
    • 13.1.1 THERMO FISHER SCIENTIFIC INC.
      • 13.1.1.1 Business overview
      • 13.1.1.2 Products offered
      • 13.1.1.3 MnM view
        • 13.1.1.3.1 Right to win
        • 13.1.1.3.2 Strategic choices
        • 13.1.1.3.3 Weaknesses & competitive threats
    • 13.1.2 KEWAUNEE SCIENTIFIC CORPORATION
      • 13.1.2.1 Business overview
      • 13.1.2.2 Products offered
      • 13.1.2.3 Recent developments
        • 13.1.2.3.1 Deals
      • 13.1.2.4 MnM view
        • 13.1.2.4.1 Right to win
        • 13.1.2.4.2 Strategic choices
        • 13.1.2.4.3 Weaknesses & competitive threats
    • 13.1.3 ESCO LIFESCIENCES GROUP
      • 13.1.3.1 Business overview
      • 13.1.3.2 Products offered
      • 13.1.3.3 Recent developments
        • 13.1.3.3.1 Product launches & approvals
        • 13.1.3.3.2 Deals
        • 13.1.3.3.3 Expansions
      • 13.1.3.4 MnM view
        • 13.1.3.4.1 Right to win
        • 13.1.3.4.2 Strategic choices
        • 13.1.3.4.3 Weaknesses & competitive threats
    • 13.1.4 LABCONCO CORPORATION
      • 13.1.4.1 Business overview
      • 13.1.4.2 Products offered
      • 13.1.4.3 Recent developments
        • 13.1.4.3.1 Product launches & approvals
      • 13.1.4.4 MnM view
        • 13.1.4.4.1 Right to win
        • 13.1.4.4.2 Strategic choices
        • 13.1.4.4.3 Weaknesses & competitive threats
    • 13.1.5 THE BAKER COMPANY, INC.
      • 13.1.5.1 Business overview
      • 13.1.5.2 Products offered
      • 13.1.5.3 Recent developments
        • 13.1.5.3.1 Product launches & approvals
      • 13.1.5.4 MnM view
        • 13.1.5.4.1 Right to win
        • 13.1.5.4.2 Strategic choices
        • 13.1.5.4.3 Weaknesses & competitive threats
    • 13.1.6 GERMFREE LABORATORIES, INC.
      • 13.1.6.1 Business overview
      • 13.1.6.2 Products offered
    • 13.1.7 CRUMA
      • 13.1.7.1 Business overview
      • 13.1.7.2 Products offered
    • 13.1.8 AIR SCIENCE USA LLC
      • 13.1.8.1 Business overview
      • 13.1.8.2 Products offered
    • 13.1.9 BERNER INTERNATIONAL GMBH
      • 13.1.9.1 Business overview
      • 13.1.9.2 Products offered
    • 13.1.10 LABOGENE
      • 13.1.10.1 Business overview
      • 13.1.10.2 Products offered
    • 13.1.11 BIOLAB SCIENTIFIC LTD.
      • 13.1.11.1 Business overview
      • 13.1.11.2 Products offered
    • 13.1.12 LAMSYSTEMS CC
      • 13.1.12.1 Business overview
      • 13.1.12.2 Products offered
  • 13.2 OTHER PLAYERS
    • 13.2.1 FASTER S.R.L.
    • 13.2.2 BIOBASE GROUP
    • 13.2.3 THERMOLAB SCIENTIFIC EQUIPMENTS PVT. LTD.
    • 13.2.4 LABMATE SCIENTIFIC LLC
    • 13.2.5 TOPAIR SYSTEMS INC.
    • 13.2.6 ZHEJIANG FUXIA MEDICAL TECHNOLOGY CO., LTD.
    • 13.2.7 BIONICS SCIENTIFIC
    • 13.2.8 SCITEK GLOBAL CO., LTD.
    • 13.2.9 HEAL FORCE BIO-MEDITECH HOLDINGS LIMITED
    • 13.2.10 SHANGHAI BOXUN MEDICAL BIOLOGICAL INSTRUMENT CORP.
    • 13.2.11 HAIER BIOMEDICAL
    • 13.2.12 HMC EUROPE GMBH
    • 13.2.13 NORDIC LABTECH AB

14 RESEARCH METHODOLOGY

  • 14.1 RESEARCH DATA
  • 14.2 RESEARCH APPROACH
    • 14.2.1 SECONDARY DATA
      • 14.2.1.1 Key data from secondary sources
    • 14.2.2 PRIMARY DATA
      • 14.2.2.1 List of primary sources
      • 14.2.2.2 Key data from primary sources
      • 14.2.2.3 Key industry insights
      • 14.2.2.4 Breakdown of primary interviews
  • 14.3 MARKET SIZE ESTIMATION
    • 14.3.1 TOTAL MARKET SIZE: BIOLOGICAL SAFETY CABINET MARKET
    • 14.3.2 BOTTOM-UP APPROACH
      • 14.3.2.1 Approach 1: Company revenue estimation approach
      • 14.3.2.2 Approach 2: Presentations of companies and primary interviews
      • 14.3.2.3 Growth forecast
      • 14.3.2.4 CAGR projections
    • 14.3.3 TOP-DOWN APPROACH
  • 14.4 DATA TRIANGULATION
  • 14.5 RESEARCH ASSUMPTIONS
    • 14.5.1 STUDY-RELATED ASSUMPTIONS
  • 14.6 STUDY ASSUMPTIONS
    • 14.6.1 PARAMETRIC ASSUMPTIONS
    • 14.6.2 GROWTH RATE ASSUMPTIONS
  • 14.7 RESEARCH LIMITATIONS
  • 14.8 RISK ASSESSMENT

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS
Show more
Product Code: MD 6299

List of Tables

  • TABLE 1 BIOLOGICAL SAFETY CABINET MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 2 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023-2030
  • TABLE 3 NORTH AMERICA: MACROECONOMIC INDICATORS
  • TABLE 4 EUROPE: MACROECONOMIC INDICATORS
  • TABLE 5 ASIA PACIFIC: MACROECONOMIC INDICATORS
  • TABLE 6 LATIN AMERICA: MACROECONOMIC INDICATORS
  • TABLE 7 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
  • TABLE 8 AVERAGE SELLING PRICE OF BIOLOGICAL SAFETY CABINET PRODUCTS, BY KEY PLAYER, 2024-2026 (USD)
  • TABLE 9 AVERAGE SELLING PRICE OF BIOLOGICAL SAFETY CABINET PRODUCTS, BY REGION, 2024-2026 (USD)
  • TABLE 10 IMPORT DATA FOR HS CODE 8414.70-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD MILLION)
  • TABLE 11 EXPORT DATA FOR HS CODE 8414.70-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD MILLION)
  • TABLE 12 BIOLOGICAL SAFETY CABINET MARKET: MAJOR CONFERENCES & EVENTS, 2026-2027
  • TABLE 13 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 14 KEY PATENTS IN BIOLOGICAL SAFETY CABINET MARKET, 2022-2026
  • TABLE 15 KEY COMPANIES IMPLEMENTING AI IN BIOLOGICAL SAFETY CABINET MARKET
  • TABLE 16 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 20 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOLOGICAL SAFETY CABINET PRODUCTS, BY TYPE (%)
  • TABLE 22 KEY BUYING CRITERIA FOR BIOLOGICAL SAFETY CABINETS, BY TYPE
  • TABLE 23 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • TABLE 24 BIOLOGICAL SAFETY CABINET MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
  • TABLE 25 BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 26 CLASS I BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 27 NORTH AMERICA: CLASS I BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 28 EUROPE: CLASS I BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 29 ASIA PACIFIC: CLASS I BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 30 CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 31 CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 32 NORTH AMERICA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 33 EUROPE: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 34 ASIA PACIFIC: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 35 CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 36 CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 37 NORTH AMERICA: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 38 EUROPE: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 39 ASIA PACIFIC: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 40 CLASS II TYPE A1 BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 41 NORTH AMERICA: CLASS II TYPE A1 BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 42 EUROPE: CLASS II TYPE A1 BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 43 ASIA PACIFIC: CLASS II TYPE A1 BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 44 CLASS II TYPE A2 BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 45 NORTH AMERICA: CLASS II TYPE A2 BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 46 EUROPE: CLASS II TYPE A2 BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 47 ASIA PACIFIC: CLASS II TYPE A2 BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 48 CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 49 CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 50 NORTH AMERICA: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 51 EUROPE: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 52 ASIA PACIFIC: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 53 CLASS II TYPE B1 BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 54 NORTH AMERICA: CLASS II TYPE B1 BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 55 EUROPE: CLASS II TYPE B1 BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 56 ASIA PACIFIC: CLASS II TYPE B1 BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 57 CLASS II TYPE B2 BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 58 NORTH AMERICA: CLASS II TYPE B2 BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 59 EUROPE: CLASS II TYPE B2 BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 60 ASIA PACIFIC: CLASS II TYPE B2 BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 61 CLASS II TYPE C1 BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 62 NORTH AMERICA: CLASS II TYPE C1 BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 63 EUROPE: CLASS II TYPE C1 BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 64 CLASS III BIOLOGICAL SAFETY CABINETS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 65 NORTH AMERICA: CLASS III BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 66 EUROPE: CLASS III BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 67 ASIA PACIFIC: CLASS III BIOLOGICAL SAFETY CABINETS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 68 BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 69 BIOLOGICAL SAFETY CABINET MARKET FOR PHARMA & BIOPHARMA ORGANIZATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 70 NORTH AMERICA: BIOLOGICAL SAFETY CABINET MARKET FOR PHARMA & BIOPHARMA ORGANIZATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 71 EUROPE: BIOLOGICAL SAFETY CABINET MARKET FOR PHARMA & BIOPHARMA ORGANIZATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 72 ASIA PACIFIC: BIOLOGICAL SAFETY CABINET MARKET FOR PHARMA & BIOPHARMA ORGANIZATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 73 BIOLOGICAL SAFETY CABINET MARKET FOR CLINICAL LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 74 NORTH AMERICA: BIOLOGICAL SAFETY CABINET MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 75 EUROPE: BIOLOGICAL SAFETY CABINET MARKET CLINICAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 76 ASIA PACIFIC: BIOLOGICAL SAFETY CABINET MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 77 BIOLOGICAL SAFETY CABINET MARKET FOR ACADEMIC & BIOMEDICAL RESEARCH INSTITUTES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 78 NORTH AMERICA: BIOLOGICAL SAFETY CABINET MARKET FOR ACADEMIC & BIOMEDICAL RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 79 EUROPE: BIOLOGICAL SAFETY CABINET MARKET FOR ACADEMIC & BIOMEDICAL RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 80 ASIA PACIFIC: BIOLOGICAL SAFETY CABINET MARKET FOR ACADEMIC & BIOMEDICAL RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 81 BIOLOGICAL SAFETY CABINET MARKET FOR OTHER END USERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 82 NORTH AMERICA: BIOLOGICAL SAFETY CABINET MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 83 EUROPE: BIOLOGICAL SAFETY CABINET MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 84 ASIA PACIFIC: BIOLOGICAL SAFETY CABINET MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 85 BIOLOGICAL SAFETY CABINET MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 86 NORTH AMERICA: MACROECONOMIC INDICATORS
  • TABLE 87 NORTH AMERICA: BIOLOGICAL SAFETY CABINET MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 88 NORTH AMERICA: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 89 NORTH AMERICA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 90 NORTH AMERICA: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 91 NORTH AMERICA: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 92 NORTH AMERICA: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 93 US BIOLOGICAL SAFETY CABINET MARKET VOLUME, 2024-2031 (UNITS)
  • TABLE 94 US: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 95 US: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 96 US: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 97 US: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 98 US: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 99 CANADA: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 100 CANADA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 101 CANADA: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 102 CANADA: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 103 CANADA: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 104 EUROPE: MACROECONOMIC INDICATORS
  • TABLE 105 EUROPE: BIOLOGICAL SAFETY CABINET MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 106 EUROPE: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 107 EUROPE: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 108 EUROPE: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 109 EUROPE: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 110 EUROPE: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 111 GERMANY: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 112 GERMANY: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 113 GERMANY: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 114 GERMANY: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 115 GERMANY: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 116 UK: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 117 UK: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 118 UK: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 119 UK: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 120 UK: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 121 FRANCE: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 122 FRANCE: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 123 FRANCE: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 124 FRANCE: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 125 FRANCE: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 126 ITALY: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 127 ITALY: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 128 ITALY: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 129 ITALY: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 130 ITALY: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 131 SPAIN: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 132 SPAIN: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 133 SPAIN: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 134 SPAIN: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 135 SPAIN: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 136 REST OF EUROPE: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 137 REST OF EUROPE: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 138 REST OF EUROPE: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 139 REST OF EUROPE: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 140 REST OF EUROPE: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 141 ASIA PACIFIC: MACROECONOMIC INDICATORS
  • TABLE 142 ASIA PACIFIC: BIOLOGICAL SAFETY CABINET MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 143 ASIA PACIFIC: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 144 ASIA PACIFIC: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 145 ASIA PACIFIC: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 146 ASIA PACIFIC: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 147 ASIA PACIFIC: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 148 CHINA: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 149 CHINA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 150 CHINA: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 151 CHINA: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 152 CHINA: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 153 JAPAN: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 154 JAPAN: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 155 JAPAN: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 156 JAPAN: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 157 JAPAN: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 158 INDIA: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 159 INDIA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 160 INDIA: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 161 INDIA: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 162 INDIA: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 163 REST OF ASIA PACIFIC: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 164 REST OF ASIA PACIFIC: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 165 REST OF ASIA PACIFIC: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 166 REST OF ASIA PACIFIC: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 167 REST OF ASIA PACIFIC: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 168 LATIN AMERICA: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 169 LATIN AMERICA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 170 LATIN AMERICA: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 171 LATIN AMERICA: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 172 LATIN AMERICA: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 173 MIDDLE EAST & AFRICA: BIOLOGICAL SAFETY CABINET MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 174 MIDDLE EAST & AFRICA: CLASS II BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 175 MIDDLE EAST & AFRICA: CLASS II TYPE A BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 176 MIDDLE EAST & AFRICA: CLASS II TYPE B BIOLOGICAL SAFETY CABINETS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 177 MIDDLE EAST & AFRICA: BIOLOGICAL SAFETY CABINET MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 178 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN BIOLOGICAL SAFETY CABINET MARKET, JANUARY 2023-AUGUST 2026
  • TABLE 179 BIOLOGICAL SAFETY CABINET MARKET: DEGREE OF COMPETITION
  • TABLE 180 BIOLOGICAL SAFETY CABINET MARKET: REGION FOOTPRINT
  • TABLE 181 BIOLOGICAL SAFETY CABINET MARKET: TYPE FOOTPRINT
  • TABLE 182 BIOLOGICAL SAFETY CABINET MARKET: END USER FOOTPRINT
  • TABLE 183 BIOLOGICAL SAFETY CABINET MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
  • TABLE 184 BIOLOGICAL SAFETY CABINET MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUP/SME PLAYERS
  • TABLE 185 BIOLOGICAL SAFETY CABINET MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 186 BIOLOGICAL SAFETY CABINET MARKET: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 187 BIOLOGICAL SAFETY CABINET MARKET: EXPANSION, JANUARY 2023-SEPTEMBER 2026
  • TABLE 188 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 189 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • TABLE 190 KEWAUNEE SCIENTIFIC CORPORATION: COMPANY OVERVIEW
  • TABLE 191 KEWAUNEE SCIENTIFIC CORPORATION: PRODUCTS OFFERED
  • TABLE 192 KEWAUNEE SCIENTIFIC CORPORATION: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 193 ESCO LIFESCIENCES GROUP: COMPANY OVERVIEW
  • TABLE 194 ESCO LIFESCIENCES GROUP: PRODUCTS OFFERED
  • TABLE 195 ESCO LIFESCIENCES GROUP: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 196 ESCO LIFESCIENCES GROUP: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 197 ESCO LIFESCIENCES GROUP: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 198 LABCONCO CORPORATION: COMPANY OVERVIEW
  • TABLE 199 LABCONCO CORPORATION: PRODUCTS OFFERED
  • TABLE 200 LABCONCO CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 201 THE BAKER COMPANY, INC.: COMPANY OVERVIEW
  • TABLE 202 THE BAKER COMPANY, INC.: PRODUCTS OFFERED
  • TABLE 203 THE BAKER COMPANY, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 204 GERMFREE LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 205 GERMFREE LABORATORIES, INC.: PRODUCTS OFFERED
  • TABLE 206 CRUMA: COMPANY OVERVIEW
  • TABLE 207 CRUMA: PRODUCTS OFFERED
  • TABLE 208 AIR SCIENCE USA LLC: COMPANY OVERVIEW
  • TABLE 209 AIR SCIENCE USA LLC: PRODUCTS OFFERED
  • TABLE 210 BERNER INTERNATIONAL GMBH: COMPANY OVERVIEW
  • TABLE 211 BERNER INTERNATIONAL GMBH: PRODUCTS OFFERED
  • TABLE 212 LABOGENE: COMPANY OVERVIEW
  • TABLE 213 LABOGENE: PRODUCTS OFFERED
  • TABLE 214 BIOLAB SCIENTIFIC LTD.: COMPANY OVERVIEW
  • TABLE 215 BIOLAB SCIENTIFIC LTD.: PRODUCTS OFFERED
  • TABLE 216 LAMSYSTEMS CC: COMPANY OVERVIEW
  • TABLE 217 LAMSYSTEMS CC: PRODUCTS OFFERED
  • TABLE 218 BIOLOGICAL SAFETY CABINET MARKET: RISK ASSESSMENT

List of Figures

  • FIGURE 1 BIOLOGICAL SAFETY CABINET MARKET SEGMENTATION
  • FIGURE 2 KEY INSIGHTS AND MARKET HIGHLIGHTS
  • FIGURE 3 GLOBAL BIOLOGICAL SAFETY CABINET MARKET, 2024-2031
  • FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN BIOLOGICAL SAFETY CABINET MARKET, 2023-2025
  • FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF BIOLOGICAL SAFETY CABINET MARKET
  • FIGURE 6 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN BIOLOGICAL SAFETY CABINET MARKET, 2026-2031
  • FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 8 INCREASING INVESTMENTS IN LABORATORY INFRASTRUCTURE AND BIOSAFETY TO DRIVE MARKET
  • FIGURE 9 CLASS II SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 10 PHARMA & BIOPHARMA ORGANIZATIONS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 11 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 12 BIOLOGICAL SAFETY CABINET MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 13 BIOLOGICAL SAFETY CABINET MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 14 BIOLOGICAL SAFETY CABINET MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 15 BIOLOGICAL SAFETY CABINET MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 16 BIOLOGICAL SAFETY CABINET MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 17 BIOLOGICAL SAFETY CABINET MARKET: TRENDS AND DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 18 NUMBER OF DEALS & FUNDING ACTIVITIES IN BIOLOGICAL SAFETY CABINET MARKET
  • FIGURE 19 PATENT ANALYSIS FOR BIOLOGICAL SAFETY CABINETS, JANUARY 2016-DECEMBER 2025
  • FIGURE 20 MARKET POTENTIAL OF AI IN BIOLOGICAL SAFETY CABINET MARKET
  • FIGURE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOLOGICAL SAFETY CABINET PRODUCTS, BY TYPE
  • FIGURE 22 KEY BUYING CRITERIA FOR BIOLOGICAL SAFETY CABINETS, BY TYPE
  • FIGURE 23 NORTH AMERICA: BIOLOGICAL SAFETY CABINET MARKET SNAPSHOT
  • FIGURE 24 ASIA PACIFIC: BIOLOGICAL SAFETY CABINET MARKET SNAPSHOT
  • FIGURE 25 REVENUE ANALYSIS OF KEY PLAYERS IN BIOLOGICAL SAFETY CABINET MARKET, 2023-2025 (USD MILLION)
  • FIGURE 26 BIOLOGICAL SAFETY CABINET MARKET SHARE ANALYSIS, 2025 (GLOBAL)
  • FIGURE 27 BIOLOGICAL SAFETY CABINET MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
  • FIGURE 28 BIOLOGICAL SAFETY CABINET MARKET: COMPANY FOOTPRINT
  • FIGURE 29 BIOLOGICAL SAFETY CABINET MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
  • FIGURE 30 EV/EBITDA OF KEY VENDORS
  • FIGURE 31 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 32 BIOLOGICAL SAFETY CABINET MARKET: PRODUCT COMPARISON FOR BIOLOGICAL SAFETY CABINET
  • FIGURE 33 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 34 KEWAUNEE SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 35 BIOLOGICAL SAFETY CABINET MARKET: RESEARCH DESIGN METHODOLOGY
  • FIGURE 36 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 37 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
  • FIGURE 38 BIOLOGICAL SAFETY CABINET MARKET: TOP-DOWN APPROACH
  • FIGURE 39 DATA TRIANGULATION METHODOLOGY
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!